How much does a box of ensifentrine-Ohtuvayre’s new COPD drug cost?

Ensifentrine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre is an innovative dual phosphodiesterase inhibitor (PDE3/4 inhibitor). Ohtuvayre is used in the treatment of patients with chronic obstructive pulmonary disease (COPD) in the form of inhalation. It is an important breakthrough in the development of COPD drugs in recent years. Its mechanism of action is unique. It achieves the dual effects of airway smooth muscle relaxation and anti-inflammatory by simultaneously inhibiting the activities of PDE3 and PDE4 enzymes. It can not only relieve dyspnea caused by airway contraction, but also improve chronic inflammatory status, thereby improving lung function and quality of life. This innovative mechanism makes it different from traditional long-acting bronchodilators or inhaled corticosteroids, providing a new treatment option for patients with moderate to severe COPD.

Currently, the original drug of ensefentin has not been officially launched in mainland China, and ordinary patients cannot obtain it through regular pharmacies. There is news from some administrative regions that the drug may be launched through special channels, but the price and medical insurance coverage have not yet been clarified, so we need to continue to pay attention to official announcements. In overseas markets, especially the United States, the U.S. version of Ohtuvayre is 3 mg/2.5 mL (60 doses/box), and each box sells for about more than 40,000 yuan. This price may fluctuate due to exchange rates, supply and demand, and import costs. In addition, there are currently no generic versions on the market, which means that the price of the original drug is still high and it will be difficult for patients to obtain medical insurance support in the short term.

Understanding overseas prices and drug specifications is of reference value to both patients and doctors. Patients can better plan for future treatment costs, and doctors can also refer to this information to evaluate drug accessibility and economic burden during clinical consultation and treatment plan formulation. With the progress of global clinical promotion and drug approval, the possibility of domestic launch and medical insurance inclusion will increase in the future, providing patients with COPD with wider accessibility and flexible treatment options, and also providing new possibilities for the long-term management of COPD.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html